PEPG - PepGen Announces Appointment of Howard Mayer M.D. to Board of Directors | Benzinga
BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023.
"We are pleased to welcome Dr. Mayer to the PepGen Board," said James McArthur, Ph.D., President and CEO of PepGen. "His extensive clinical development and regulatory experience across a variety of therapeutic areas, including multiple global regulatory filings and approvals in rare diseases, will be invaluable to PepGen as we create the new generation of genetic therapies for devastating neuromuscular diseases."
Dr. Mayer was most recently Executive Vice President, Head of Research and Development at Ipsen Pharmaceuticals from 2019 until 2023. He was previously Senior Vice President, Chief Medical Officer at Shire Pharmaceuticals. Before joining Shire Pharmaceuticals, Dr. Mayer served as Chief Medical Officer at EMD Serono, a division of Merck KGaA, and held a variety of global roles at Pfizer Inc. and Bristol-Myers Squibb prior to that.
Dr. Mayer obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical ...